Merriman Curhan Ford Reiterates 'Buy' Geron Corporation (GERN); Important Stem Cell Visibility
More News related to GERN
- Geron (GERN) Presents Interim Data from Imetelstat at AACR-NCI-EORTC Int. Conference
- Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC
- Geron to Present at LCM Healthcare Conference
- Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
- Geron Corp. (GERN) Reports that hESC-Derived Oligodendrocyte Progenitor Cells Reduced Cervical Spinal Cord Injury
More News related to Analyst Comments
- State Street (STT) to Provide Investment Manager Operations Outsourcing Services For $300B in MSIM Assets
- Capstone Turbine (CPST) Introduces CMT-380 Hybrid Supercar; To Debut at LA Auto Show
- Northrop Grumman (NOC) Delivers New Version of FBCB2 to U.S. Army
- Constellation Energy (CEG) to Acquire Criterion Wind Project in Garrett County, Md
- eBay (EBAY) Issues Response to French Court LVMH Ruling
Merriman Curhan Ford reiterates 'Buy' Geron Corporation (Nasdaq: GERN), valuation range $9-10.
Merriman analyst says, "We view Geron as the established leader in establishing therapeutics against telomerase, which plays an important role in cancer cells. The company is targeting telomerase through direct inhibition and through an immunotherapy (vaccine) approach. To this end, the company’s lead product GRN163L is in multiple clinical trials and represents a promising new cancer therapeutic. Geron also is poised to be a key leader in the embryonic stem cell arena. While volatility is still expected from the stem cell platform at Geron, we believe the increased visibility and data flow from the telomerase program should drive the stock going forward."
To see more analyst ratings on GERN Click Here.
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
Related Categories
Analyst CommentsStocks Mentioned
-0.05Related Entities
Comments
gern stem cell research
merriman curhan ford has the brightest outlook on stem cell progress ive seen we are behind you all the way think your doing great job in pushing this stem cell research project life saver in the future
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
stem cell
sol on Nov 8, 2009 06:23 PMgern,stem, astm are winners. President obama needs to give the funding he promised. In the last month 3 operations have been used with stem cell. For everyone out there you can use your own stem cell. YOU DON'T HAVE TO KILL EMBRYO'S. Read and educate. Stem cell is saving lives now.